such as tissue plasminogen activator, urokinase, or a bacterial enzyme.

9. The use of any of claims 5 to 8, wherein the Annexin A5 or the functional analogue or variant thereof is to be administered in conjunction with an anti-platelet agent such as clopidogrel or aspirin.

10. The use of any of the preceding claims, wherein the Annexin A5 or the functional analogue or variant thereof is selected from;
    a) human Annexin A5 (SEQ ID NO:1),
    b) a mammalian orthologue of human Annexin A5,
    c) an allelic or genetic variant of a) or b),
    d) a functional analogue of Annexin A5 which is a protein which is more than 95% identical to human Annexin A5, SEQ ID NO: 1,
    e) a dimer of, or fusion protein comprising, any of a), b), c) or d), and
    f) a PEGylated variant of any of a), b), c), d) or e).

11. The use of any of the preceding claims, wherein the therapeutically effective amount of Annexin A5 or the functional analogue or variant thereof is to be administered parenterally, intravenously, intra-arterially, intra-peritoneally, intramuscularly or subcutaneously.

~~12. Annexin A5 or a functional analogue or variant thereof for use in the treatment of vascular dysfunction associated with impaired endothelium mediated vasodilatation, a reduced endothelial nitric oxide synthase (eNOS) activity, and/or a reduced nitric oxide (NO) bioavailability, wherein the functional analogue or variant of Annexin A5 comprises a protein which is more than 90% identical to human Annexin A5, SEQ ID NO:1.~~

~~13. Annexin A5 or a functional analogue or variant thereof for use in reducing ischemic pain, wherein the functional analogue or variant of Annexin A5 comprises a protein which is more than 90% identical to human Annexin A5, SEQ ID NO:1.~~

~~14. Annexin A5 or a functional analogue or variant thereof according to claim 12 or 13, for use in reducing the risk of the onset of acute myocardial infarction (AMI).~~

15. Annexin A5 or a functional analogue or variant thereof according to any of claim 12, 13 or 14, wherein the patient treated is suffering from a disease selected from angina pectoris, ischaemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.

16. Annexin A5 or a functional analogue or variant thereof for use in the treatment, prevention, or reduction of risk of onset of a vascular disease that is associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability, wherein the functional analogue or variant of Annexin A5 comprises a protein which is more than 90% identical to human Annexin A5, SEQ ID NO:1.

17. Annexin A5 or a functional analogue or variant thereof according to claim 16, wherein the treatment reduces the risk of the onset of acute myocardial infarction (AMI).

18. Annexin A5 or a functional analogue or variant thereof according to claim 16 or 17, wherein the vascular disease is selected from angina pectoris, ischaemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.

19. Annexin A5 or a functional analogue or variant thereof according to any of claims 16, 17 or 18, wherein the Annexin A5 or the functional analogue or variant thereof is to be administered in conjunction with a thrombolytic therapeutic such as tissue plasminogen activator, urokinase, or a bacterial enzyme.

20. Annexin A5 or a functional analogue or variant thereof according to any of claims 16 to 19, wherein the Annexin A5 or the functional analogue or variant thereof is to be administered in conjunction with an anti-platelet agent such as clopidogrel or aspirin.

21. Annexin A5 or a functional analogue or variant thereof according to any of claims 12 to 20, wherein the Annexin A5 or the functional analogue or variant thereof is selected from;

a) human Annexin A5 (SEQ ID NO:1),

b) a mammalian orthologue of human Annexin A5,

c) an allelic or genetic variant of a) or b),

d) a functional analogue of Annexin A5 which is a protein which is more than 95%

identical to human Annexin A5, SEQ ID NO: 1,

e) a dimer of, or fusion protein comprising, any of a), b), c) or d), and

f) a PEGylated variant of any of a), b), c), d) or e).

22. Annexin A5 or a functional analogue or variant thereof according to any one of claims 12 to 21, which is to be administered parenterally, intravenously, intra-arterially, intra-peritoneally, intra-muscularly or subcutaneously.